Criteria derived from serum markers can precisely evaluate axillary status in breast cancer patients

Wan, Hangyu; Du, Zhenggui; Long, Quanyi; Lü, Qing; Li, Hongjiang

doi:10.1016/j.jss.2016.08.086

Cited by 7 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, the CCL5/CCR5 axis, which can recruit CD4 + and CD8 + T cells [77] and NK cells [42], can predict the improved efficiency of DC-immunotherapy in NSCLC [78]. Nevertheless, this pair also exhibits chemoattraction to TAMs and MDSCs [79,80], and has been reported to correlate with poor outcomes in BC patients [81].…”

Section: Myeloid-derived Suppressor Cells (Mdscs)mentioning

confidence: 99%

“…The CCL5/CCR5 axis has been demonstrated to promote cancer cell migration through the recruitment and modulation of inflammatory cell activities, followed by the generation of an immunosuppressive environment including TAMs and MDSCs in BC [79,80,161]. Data from a study on BC patients showed that patients with higher serum levels of CCL5 had a greater probability of lymph node metastasis [81]. Similarly, in stage II BC patients, the positive tumor expression of CCL5 alone or when combined with the absence of estrogen receptor-α significantly increased the risk for disease progression [162].…”

Section: Ccl5mentioning

confidence: 99%

See 1 more Smart Citation

Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers

Thu

Lee

Cho

2020

Cancers

160

131

View full text Add to dashboard Cite

Chemokines are chemotactic cytokines that mediate immune cell chemotaxis and lymphoid tissue development. Recent advances have indicated that chemokines and their cognate receptors play critical roles in cancer-related inflammation and cancer progression. On the basis of these findings, the chemokine system has become a new potential drug target for cancer immunotherapy. In this review, we summarize the essential roles of the complex network of chemokines and their receptors in cancer progression. Furthermore, we discuss the potential value of the chemokine system as a cancer prognostic marker. The chemokine system regulates the infiltration of immune cells into the tumor microenvironment, which induces both pro- and anti-immunity and promotes or suppresses tumor growth and proliferation, angiogenesis, and metastasis. Increasing evidence indicates the promising prognostic value of the chemokine system in cancer patients. While CCL2, CXCL10, and CX3CL1/CX3CR1 can serve as favorable or unfavorable prognostic factors depending on the cancer types, CCL14 and XCL1 possess good prognostic value. Other chemokines such as CXCL1, CXCL8, and CXCL12 are poor prognostic markers. Despite vast advances in our understanding of the complex nature of the chemokine system in tumor biology, knowledge about the multifaceted roles of the chemokine system in different types of cancers is still limited. Further studies are necessary to decipher distinct roles within the chemokine system in terms of cancer progression and to validate their potential value in cancer prognosis.

show abstract

Section: Myeloid-derived Suppressor Cells (Mdscs)mentioning

confidence: 99%

Section: Ccl5mentioning

confidence: 99%

Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers

Thu

Lee

Cho

2020

Cancers

160

131

View full text Add to dashboard Cite

show abstract

“…Passage of cells was performed once every 2 or 3 days, and cells in the logarithmic growth phase were collected for the following experiments. (Wan, Du, Long, Lü, & Li, 2017).…”

Section: )mentioning

confidence: 99%

Retracted: Inhibitory role of large intergenic noncoding RNA‐ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway

Lü

Wang

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Breast cancer (BC) is the second-leading cause of central nervous system metastases among severe malignancies. This study aimed at investigating the underlying mechanism by which large intergenic noncoding RNA-regulator of reprogramming (lincRNA-ROR) affects the tamoxifen (TAM) resistance of BC cells by regulating the PI3K/Akt/mTOR signaling pathway. Immortalized human mammary epithelial cell line (MCF10A) and BC cell lines (MCF-7, MDA-MB-231, T47D, BCAP-37, and ZK-75-1) were cultured, and BC tissues and adjacent normal breast tissues were collected from 152 BC patients. LincRNA-ROR expression in tissues and cells were detected using reverse transcription quantitative polymerase chain reaction. RNA interference was used to silence lincRNA-ROR in MDA-MB-231 cells, and then the cell proliferation and apoptosis were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and annexin-V and propidium iodide (PI) double staining respectively. The expression of apoptosis-related proteins and PI3K/Akt/mTOR signaling pathway-related proteins was measured by performing western blot assay. The BC tissues and cells presented a higher expression of lincRNA-ROR. MAD-MB-231 cells exhibited the highest lincRNA-ROR expression. After lincRNA-ROR silencing, MAD-MB-231 cells showed decreased proliferation, and increased sensitivity to TAM. Besides, the apoptosis-promoting effect of TAM on MAN-MB-231 cells significantly increased. The expression of PI3K/Akt/mTOR signaling pathway-related proteins and the PI3K/Akt/mTOR signaling pathway were repressed by TAM after silencing lincRNA-ROR. Our study demonstrated that silencing lincRNA-ROR could increase the sensitivity of BC MAD-MB-231 cells to TAM by suppressing the activation of P13K/Akt/mTOR signaling pathway.

show abstract

“…Our previous study found that CCL5 in serum may be positively correlated with lymph node metastasis in breast cancer ( 21 ), but the source of CCL5 in vivo and the reasons for its correlation with lymph node metastasis are still unclear. Therefore, this study focused on the receptors and pathways related to the CCL5 protein to study the role and possible mechanism of CCL5 in the metastasis of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

CCL5 mediates breast cancer metastasis and prognosis through CCR5/Treg cells

Zeng

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Background and aimsCCL5 is considered to contribute to the biological function of a variety of cancer types, but its specific mechanism is still unclear. This study aimed to reveal the mechanism of CCL5 in the invasion, metastasis, and prognosis of breast cancer.MethodsThe expression of CCL5 in tumor tissue and serum was measured with a Luminex protein detection kit, and the correlation between CCL5 and clinical parameters was evaluated. Kaplan–Meier analysis was used to analyze the effect of CCL5 on the prognosis of breast cancer patients. Protein interaction network analysis and gene coexpression were used to determine the receptor that has the strongest interaction with CCL5. Enrichment analysis was used to study the possible pathway by which CCL5 affects breast cancer progression. We used immunofluorescence staining and flow cytometry to estimate the fraction of immunity-related components in the tumor microenvironment.ResultsThe expression level of CCL5 in breast cancer patients was positively correlated with the degree of axillary lymph node metastasis; CCL5 in tumor tissue was correlated with estrogen receptor status (P = 0.034), progesterone receptor (P = 0.009), nuclear grade (P = 0.013), clinical stage (P < 0.001) and molecular subtype (P = 0.024) in breast cancer patients. Breast cancer patients with high CCL5 expression had worse disease-free survival (P = 0.031) and breast cancer-specific survival (P = 0.043); however, CCL5 had no effect on overall survival (P = 0.077). CCL5 affected tumor progression through CCR5, and the T-cell-related immune pathway may be the main pathway; the CD4+/CD8+, CCR5+/CD4+ and Treg/CCR5+ cell ratios were significantly increased in the lymph node metastasis group.ConclusionCCL5 affects the Treg/CD4+CCR5+ cell ratio in breast cancer patients through CCR5, thus affecting breast cancer metastasis and prognosis.

show abstract

Criteria derived from serum markers can precisely evaluate axillary status in breast cancer patients

Cited by 7 publications

References 29 publications

Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers

Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers

Retracted: Inhibitory role of large intergenic noncoding RNA‐ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway

CCL5 mediates breast cancer metastasis and prognosis through CCR5/Treg cells

Contact Info

Product

Resources

About